Drug intelligence / Profile preview

diltiazem + olmesartan medoxomil

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two separate medications used together for hypertension treatment. Diltiazem is a calcium channel blocker that inhibits calcium influx across cell membranes in cardiac and vascular smooth muscle. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. When used together, these medications may have complementary effects on blood pressure through different mechanisms, but also potential for additive effects that require monitoring.

Targets

LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on diltiazem + olmesartan medoxomil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diltiazem + olmesartan medoxomil.

Explore the full profile